Hormone therapy and estrogen receptor expression in breast cancer

References

• Pritchard KI. Hormone replacement in women with a history of breast cancer. Oncologist 2001; 6: 353–62
   PubMedGoogle Scholar
• Collaborative group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of individual data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer from 54 epidemiological studies. Lancet 1997; 350: 1047–59
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 3: 321–33
   Google Scholar
• Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004; 14: 1701–12
   Google Scholar
• Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003; 362: 419–27
   PubMed Web of Science ®Google Scholar
• Gapstur S, Morrow M, Sellers T. Hormone replacement therapy and risk of breast cancer with a favourable histology. JAMA 1999; 281: 2091–7
   PubMed Web of Science ®Google Scholar
• Bonnier P, Besseney F, Sasco A, Beedassy B, Lejeune C, Romain S, et al. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 1998; 79: 278–82
   PubMed Web of Science ®Google Scholar
• Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet 2005; 365: 1727–41
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. International consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817–27
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451–67
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen: Result of a prospective Southwest Oncology Group Study. J Clin Oncol 1992; 10: 1284–91
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Neven P. Endometrial safety of hormone replacement therapy: Review of literature. Maturitas 2002; 42: 93–104
   PubMed Web of Science ®Google Scholar
• Reid SE, Murphy MS, Kaufman M, Scanlon EF. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996; 83: 1037–46
   PubMed Web of Science ®Google Scholar
• Jernström H, Frenander J, Fernö M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 1999; 89: 1453–8
   Google Scholar
• Magnusson C, Holmberg L, Nordén T, Lindgren A, Persson I. Prognostic characteristics in breast cancer after hormone replacement therapy. Breast Cancer Res Treat 1996; 38: 325–34
   PubMed Web of Science ®Google Scholar
• Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382–93
   PubMed Web of Science ®Google Scholar
• Pujol P, Daures J-P, Thezenas S, Guilleux F, Rouanet P, Grenier J. Changing estrogen and progesterone patterns in breast carcinoma during the menstrual cycle and menopause. Cancer 1998; 83: 698–705
   PubMed Web of Science ®Google Scholar
• Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios; a prospective Danish cohort study. Cancer 2004; 100: 2328–37
   PubMed Web of Science ®Google Scholar
• Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004; 101: 1490–500
   PubMed Web of Science ®Google Scholar
• Cline JM, Soderqvist G, von Schoultz B, Skoog L, von Schoultz E. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal macaques. Am J Obstet Gynecol 1996; 174: 93–100
   PubMed Web of Science ®Google Scholar
• Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84: 4559–65
   PubMed Web of Science ®Google Scholar